Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Polymers: Molecular Weight Distribution01:10

Polymers: Molecular Weight Distribution

4.0K
For any given polymer, the weight average molecular weight (Mw) is higher than, if not equal to, the number average molecular weight (Mn). The only situation in which the weight average molecular weight and the number average molecular weight are equal is when a polymer consists only of chains with equal molecular weight. However, this never happens in a synthetic polymer, since it is difficult to control the polymerization process up to a molecular level with accuracy to a hundred percent.
4.0K
Drug Distribution: Volume of Distribution01:25

Drug Distribution: Volume of Distribution

7.3K
The volume of distribution refers to the theoretical volume necessary to contain the entire amount of an administered drug at the same concentration observed in the blood plasma. The body's intracellular fluid compartment, which makes up two-thirds of the total body water, is contrasted with the extracellular fluid compartment—comprising plasma and interstitial fluid—that accounts for one-third. The volume of distribution can vary depending on the characteristics of the drug.
7.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conserved and sexually dimorphic behavioral responses to biogenic amines in decapitated Drosophila.

Proceedings of the National Academy of Sciences of the United States of America·1997
Same author

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.

Annals of internal medicine·1997
Same author

Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.

Circulation·1997
Same author

Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.

Circulation·1996
Same author

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.

Haemostasis·1996
Same author

Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo.

Blood·1996
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

15.4K

Low molecular weight heparin

J Hirsh1

  • 1McMaster University, Hamilton, Ontario, Canada.

Thrombosis and Haemostasis
|July 1, 1993
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

7.1K
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

604

Related Experiment Videos

Last Updated: May 2, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

15.4K
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

7.1K
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

604